Company
United StatesPublic company, NASDAQ: LINLinde Inc. (NASDAQ: LIN), Baltimore, MD – FDA Inspections
Inspection records and compliance data for Linde Inc. in Baltimore, Maryland. 2 FDA inspections on record, last inspected May 28, 2026. Publicly traded as NASDAQ: LIN.
Company Profile
This profile covers Linde Inc. based in Baltimore, Maryland, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected November 14, 2013. Last inspected May 28, 2026.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| May 28, 2026 | NAI | Human Drugs · Drug Quality Assurance | 1319642 |
| November 14, 2013 | NAI | Human Drugs · Drug Quality Assurance | 855169 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Linde Inc.
Stock ticker
LIN
Exchange
NASDAQ
Share price
$521.47
Market cap
$239.4B
Price as of
November 6, 2026
FEI Number
1119501
Address
7350 Carbide Rd, Baltimore, Maryland 21226, United States
Country
United States
ID: 5d3cc304-5931-4cc5-bb47-eef2a089bcd5